Header Logo

Connection

Kamyar Kalantar-Zadeh M.D. to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications Kamyar Kalantar-Zadeh M.D. has written about Cardiovascular Diseases.
Kamyar Kalantar-Zadeh M.D.
Connection Strength
13.435
Cardiovascular Diseases
  1. Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021 05 08; 16(5):705-716.
    View in: PubMed
    Score: 0.620
  2. The quest for cardiovascular disease risk prediction models in patients with nondialysis chronic kidney disease. Curr Opin Nephrol Hypertens. 2021 01; 30(1):38-46.
    View in: PubMed
    Score: 0.607
  3. Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease. Curr Opin Nephrol Hypertens. 2020 01; 29(1):4-15.
    View in: PubMed
    Score: 0.566
  4. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.
    View in: PubMed
    Score: 0.555
  5. Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA Netw Open. 2018 10 05; 1(6):e182311.
    View in: PubMed
    Score: 0.519
  6. Predialysis Kidney Function and Its Rate of Decline Predict Mortality and Hospitalizations After Starting Dialysis. Mayo Clin Proc. 2018 08; 93(8):1074-1085.
    View in: PubMed
    Score: 0.510
  7. Thyroid Status and Mortality in a Prospective Hemodialysis Cohort. J Clin Endocrinol Metab. 2017 05 01; 102(5):1568-1577.
    View in: PubMed
    Score: 0.470
  8. Increased Risk of Incident Chronic Kidney Disease, Cardiovascular Disease, and Mortality in Patients With Diabetes With Comorbid Depression. Diabetes Care. 2016 Nov; 39(11):1940-1947.
    View in: PubMed
    Score: 0.443
  9. Predialysis Cardiovascular Disease Medication Adherence and Mortality After Transition to Dialysis. Am J Kidney Dis. 2016 Oct; 68(4):609-618.
    View in: PubMed
    Score: 0.437
  10. Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. J Am Med Dir Assoc. 2015 Nov 01; 16(11):933-9.
    View in: PubMed
    Score: 0.420
  11. Changes in pulse pressure during hemodialysis treatment and survival in maintenance dialysis patients. Clin J Am Soc Nephrol. 2015 Jul 07; 10(7):1179-91.
    View in: PubMed
    Score: 0.412
  12. Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients. Nephrol Dial Transplant. 2015 May; 30(5):724-37.
    View in: PubMed
    Score: 0.377
  13. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant. 2014 Aug; 29(8):1554-62.
    View in: PubMed
    Score: 0.377
  14. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol. 2013; 38(2):136-48.
    View in: PubMed
    Score: 0.363
  15. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease. J Am Coll Cardiol. 2013 Apr 16; 61(15):1626-33.
    View in: PubMed
    Score: 0.355
  16. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012 Mar; 61(3):708-15.
    View in: PubMed
    Score: 0.327
  17. Dietary intake in hemodialysis patients does not reflect a heart healthy diet. J Ren Nutr. 2011 Nov; 21(6):438-47.
    View in: PubMed
    Score: 0.303
  18. Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs. 2008 Apr; 17(4):451-67.
    View in: PubMed
    Score: 0.251
  19. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007 Jul; 10(4):433-42.
    View in: PubMed
    Score: 0.238
  20. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis. 2006 Jul; 48(1):37-49.
    View in: PubMed
    Score: 0.222
  21. The latest addition to the inflammatory homeboys in chronic kidney disease: interleukin-8. Nephron Clin Pract. 2006; 102(2):c59-60.
    View in: PubMed
    Score: 0.214
  22. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005 Sep; 46(3):489-500.
    View in: PubMed
    Score: 0.210
  23. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005 Sep; 20(9):1880-8.
    View in: PubMed
    Score: 0.206
  24. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension. 2005 Apr; 45(4):811-7.
    View in: PubMed
    Score: 0.201
  25. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003 Mar; 63(3):793-808.
    View in: PubMed
    Score: 0.176
  26. Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans). Am J Cardiol. 2022 05 01; 170:47-55.
    View in: PubMed
    Score: 0.165
  27. Risk of Atherosclerotic Cardiovascular Disease and Nonatherosclerotic Cardiovascular Disease Hospitalizations for Triglycerides Across Chronic Kidney Disease Stages Among 2.9?Million US Veterans. J Am Heart Assoc. 2021 12 07; 10(23):e022988.
    View in: PubMed
    Score: 0.161
  28. Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort. Am J Nephrol. 2021; 52(3):199-208.
    View in: PubMed
    Score: 0.154
  29. Association of lactate dehydrogenase with mortality in incident hemodialysis patients. Nephrol Dial Transplant. 2021 03 29; 36(4):704-712.
    View in: PubMed
    Score: 0.154
  30. Editorial: Novel therapeutic approaches in chronic kidney disease, uremia and kidney transplantation: past, present and future. Curr Opin Nephrol Hypertens. 2021 01; 30(1):1-4.
    View in: PubMed
    Score: 0.152
  31. The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD. J Med Econ. 2020 Mar; 23(3):308-315.
    View in: PubMed
    Score: 0.141
  32. Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes. J Am Heart Assoc. 2019 03 19; 8(6):e011869.
    View in: PubMed
    Score: 0.134
  33. Apabetalone downregulates factors and pathways associated with vascular calcification. Atherosclerosis. 2019 01; 280:75-84.
    View in: PubMed
    Score: 0.131
  34. The Obesity Paradigm and Lifetime Risk of Cardiovascular Disease. JAMA Cardiol. 2018 09 01; 3(9):895-896.
    View in: PubMed
    Score: 0.129
  35. Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease. Kidney Blood Press Res. 2018; 43(2):449-457.
    View in: PubMed
    Score: 0.125
  36. Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. J Clin Lipidol. 2018 Mar - Apr; 12(2):488-497.
    View in: PubMed
    Score: 0.124
  37. Association of Ultrafiltration Rate with Mortality in Incident Hemodialysis Patients. Nephron. 2018; 139(1):13-22.
    View in: PubMed
    Score: 0.124
  38. Association between Testosterone and Mortality Risk among U.S. Males Receiving Dialysis. Am J Nephrol. 2017; 46(3):195-203.
    View in: PubMed
    Score: 0.120
  39. Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol. 2017 07; 13(7):429-442.
    View in: PubMed
    Score: 0.118
  40. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol. 2017 Apr 03; 12(4):591-602.
    View in: PubMed
    Score: 0.116
  41. Association of Slopes of Estimated Glomerular Filtration Rate With Post-End-Stage Renal Disease Mortality in Patients With Advanced Chronic Kidney Disease Transitioning to Dialysis. Mayo Clin Proc. 2016 Feb; 91(2):196-207.
    View in: PubMed
    Score: 0.108
  42. Cardiovascular and Renal Outcomes Trials-Is There a Difference? Am J Cardiol. 2015 Sep 15; 116(6):982-8.
    View in: PubMed
    Score: 0.103
  43. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015 Sep; 88(3):622-32.
    View in: PubMed
    Score: 0.102
  44. Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. Am J Kidney Dis. 2015 Aug; 66(2):313-21.
    View in: PubMed
    Score: 0.102
  45. Association of thyroid functional disease with mortality in a national cohort of incident hemodialysis patients. J Clin Endocrinol Metab. 2015 Apr; 100(4):1386-95.
    View in: PubMed
    Score: 0.101
  46. Alkaline phosphatase: better than PTH as a marker of cardiovascular and bone disease? Hemodial Int. 2014 Oct; 18(4):720-4.
    View in: PubMed
    Score: 0.098
  47. Effect of age and dialysis vintage on obesity paradox in long-term hemodialysis patients. Am J Kidney Dis. 2014 Apr; 63(4):612-22.
    View in: PubMed
    Score: 0.092
  48. Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients. J Ren Nutr. 2013 Nov; 23(6):411-21.
    View in: PubMed
    Score: 0.089
  49. Patterns and predictors of early mortality in incident hemodialysis patients: new insights. Am J Nephrol. 2012; 35(6):548-58.
    View in: PubMed
    Score: 0.084
  50. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol. 2012 Aug; 7(8):1272-84.
    View in: PubMed
    Score: 0.084
  51. Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort. J Hypertens. 2011 Nov; 29(11):2226-35.
    View in: PubMed
    Score: 0.080
  52. Association of pretransplant serum phosphorus with posttransplant outcomes. Clin J Am Soc Nephrol. 2011 Nov; 6(11):2712-21.
    View in: PubMed
    Score: 0.080
  53. Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis. Am J Kidney Dis. 2011 Sep; 58(3):418-28.
    View in: PubMed
    Score: 0.078
  54. Introduction: the reverse epidemiology controversy. Semin Dial. 2007 Nov-Dec; 20(6):485.
    View in: PubMed
    Score: 0.061
  55. What is so bad about reverse epidemiology anyway? Semin Dial. 2007 Nov-Dec; 20(6):593-601.
    View in: PubMed
    Score: 0.061
  56. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007 May; 30(5):1049-55.
    View in: PubMed
    Score: 0.058
  57. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007 Jan; 18(1):293-303.
    View in: PubMed
    Score: 0.057
  58. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol. 2007 Jan; 18(1):304-11.
    View in: PubMed
    Score: 0.057
  59. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodial Int. 2006 Oct; 10(4):315-25.
    View in: PubMed
    Score: 0.056
  60. Hepatitis C infection in dialysis patients: a link to poor clinical outcome? Int Urol Nephrol. 2007; 39(1):247-59.
    View in: PubMed
    Score: 0.056
  61. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005 Oct; 16(10):3070-80.
    View in: PubMed
    Score: 0.052
  62. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant. 2005 Aug; 20(8):1662-9.
    View in: PubMed
    Score: 0.051
  63. Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif. 2005; 23(1):57-63.
    View in: PubMed
    Score: 0.050
  64. Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr. 2004 Apr; 14(2):64-71.
    View in: PubMed
    Score: 0.047
  65. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. J Alzheimers Dis. 2021; 83(4):1703-1715.
    View in: PubMed
    Score: 0.038
  66. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2020 04 28; 323(16):1565-1573.
    View in: PubMed
    Score: 0.036
  67. Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. J Clin Lipidol. 2019 Sep - Oct; 13(5):744-753.e15.
    View in: PubMed
    Score: 0.034
  68. World kidney day 2016 Averting the legacy of kidney disease--- focus on childhood. Clin Nephrol. 2016 Feb; 85(2):63-9.
    View in: PubMed
    Score: 0.027
  69. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct; 37(10):2864-83.
    View in: PubMed
    Score: 0.025
  70. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013 Oct; 88(10):1099-107.
    View in: PubMed
    Score: 0.023
  71. The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med. 2009 Nov; 25(4):643-59, viii.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.